Login to Your Account

Clinic Roundup

Monday, February 28, 2011
Helix BioPharma Corp., of Aurora, Ontario, filed a clinical trial application with the Polish Ministry of Health for a planned Phase I/II study of lung cancer candidate L-DOS47, an immunoconjugate drug developed using the DOS47 technology. The open-label trial is designed to test the efficacy of the drug alone and in combination with chemotherapy or radiation therapy and will enroll patients with inoperable, locally advanced, recurrent or metastatic nonsquamous non-small-cell lung cancer. The multi-arm study will include about 30 to 50 patients in each treatment arm in order to reach the maximum-tolerated dose.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription